Evidence map›Paper›PMID 35033881›Full record

ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2022

A quantitative assay for detection of SARS-CoV-2 neutralizing antibodies.

Helena Cerutti, Tommaso Bandini, Marinunzia Castria, Alessandra Cartocci, Veronica Ricci, Stefania Tornesi, Alessia Bogi, Giulia Tesi, Claudia Soldatini, Simona Toppi and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Helena CeruttiDiesse Diagnostica Senese SpA, Siena, Italy; Diesse Diagnostica Senese SpA, R&D Biotechnology Research Site: Via Fiorentina, 1 - c/o Toscana Life Sciences, Siena, Italy. Electronic address: helenacerutti@diesse.it.
Tommaso BandiniDiesse Diagnostica Senese SpA, Siena, Italy; Diesse Diagnostica Senese SpA, R&D Development Site: Via delle Rose, Monteriggioni, Italy.
Marinunzia CastriaDiesse Diagnostica Senese SpA, Siena, Italy; Diesse Diagnostica Senese SpA, R&D Biotechnology Research Site: Via Fiorentina, 1 - c/o Toscana Life Sciences, Siena, Italy.
Alessandra CartocciDepartment of Medical Biotechnology, University of Siena, Siena, Italy.
Veronica RicciDiesse Diagnostica Senese SpA, Siena, Italy; Diesse Diagnostica Senese SpA, Production Site: Via delle Rose, Monteriggioni, Italy.
Stefania TornesiDiesse Diagnostica Senese SpA, Siena, Italy; Diesse Diagnostica Senese SpA, Production Site: Via delle Rose, Monteriggioni, Italy.
Alessia BogiDiesse Diagnostica Senese SpA, Siena, Italy; Diesse Diagnostica Senese SpA, R&D Development Site: Via delle Rose, Monteriggioni, Italy.
Giulia TesiDiesse Diagnostica Senese SpA, Siena, Italy; Diesse Diagnostica Senese SpA, R&D Biotechnology Research Site: Via Fiorentina, 1 - c/o Toscana Life Sciences, Siena, Italy.
Claudia SoldatiniDiesse Diagnostica Senese SpA, Siena, Italy; Diesse Diagnostica Senese SpA, R&D Biotechnology Research Site: Via Fiorentina, 1 - c/o Toscana Life Sciences, Siena, Italy.
Simona ToppiDiesse Diagnostica Senese SpA, Siena, Italy; Diesse Diagnostica Senese SpA, Production Site: Via delle Rose, Monteriggioni, Italy.
Alessandra BrogiDiesse Diagnostica Senese SpA, Siena, Italy; Diesse Diagnostica Senese SpA, R&D Biotechnology Research Site: Via Fiorentina, 1 - c/o Toscana Life Sciences, Siena, Italy.
Azienda Ospedaliera Universitaria Senese · ITDIESSE Diagnostica Senese S.p.A. Società Benefit (Italy)Toscana Life Sciences · ITUniversity of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesSerological assays for SARS-CoV-2 have a critical role not only in diagnosis of COVID-19, but also in assessing the degree and duration of response of specific antibodies against the virus obtained through infection or vaccination. We present the results obtained with a competitive immunoenzymatic method (Chorus SARS-CoV-2 "Neutralizing" Ab) for quantitative determination of total neutralizing anti-S1 SARS-CoV-2 antibodies (IgG, IgM, and IgA) in human serum obtained on a disposable device with the Chorus TRIO instrument using a recombinant strong neutralizing antibody as tracer.

methodsA total of 694 sera were evaluated for SARS-CoV-2 neutralizing antibodies: 407 uninfected, 201 symptomatic subjects, 37 post-infection patients, and 49 vaccinated. Sixty-eight of the previous sera were used to compare the Chorus SARS-CoV-2 "Neutralizing" Ab results with those obtained with micro-neutralization of the Alpha and original variants. A set of 74 positive sera for other respiratory infections were analyzed to evaluate the possible cross reaction to SARS-CoV-2 virus.

resultsOf the 694 samples, only 3 had discordant results between micro-neutralization and values measured by Chorus SARS-CoV-2 "Neutralizing" Ab: 1 false negative and 2 false positives. Values of sensitivity and specificity were very high: percent positive agreement (sensitivity) 99.6% (95% CI: 97.7 - 99.9) and percent negative agreement (specificity) 99.6% (95% CI: 98.0 -99.9). Concordance was high with a Gwet's Ac1 of 0.992. No significant differences were observed between the alpha and original variants.

conclusionsThe Chorus SARS-CoV-2 "Neutralizing" Ab test was highly sensitive and specific, and varies from most other currently available tests since it analyzes only antibodies with viral-neutralizing capacity.

Indexed as

COVID-19SARS-CoV-2Antibodies, NeutralizingAntibodies, ViralCOVID-19 Serological TestingHumansSensitivity and SpecificitySpike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, CoronavirusCOVID-19Diagnostic assayImmunoassayNeutralizing antibodiesSARS-CoV-2

Identifiers

PMID35033881
PMCPMC8720384
OpenAlexW4205198000

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.